Research programme: Alzheimer's disease therapy - Myriad Pharmaceuticals
Alternative Names: MPI 127585; MPI 423948; MPI-442690; MPYS 315Latest Information Update: 25 Sep 2009
At a glance
- Originator Mayo Clinic
- Developer Myriad Pharmaceuticals
- Class
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 25 Sep 2009 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 17 Aug 2007 Preclinical development is ongoing
- 17 Jun 2005 This programme is still in active development